Amanda Przespolewski

Medical Oncology
2023 Buffalo Spree Top Doctors Badge

Dr. Przespolewski is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2023

Cancers Treated:

Specializing In:

Acute myeloid leukemia (AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myeloproliferative diseases (MPD) Myelodysplastic syndrome (MDS) Hematologic Oncology

Research Interests:

Bone Marrow Microenvironment Immunotherapy Early Phase Clinical Trials Translational Medicine

About Amanda Przespolewski


I joined the Leukemia Service within the Department of Medicine at Roswell Park in July 2017. I treat patients with both malignant and non-malignant blood disorders. This includes patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. As a native of Buffalo, NY, I completed a large portion of my training locally. I received my doctoral degree in 2011 from the Lake Erie College of Osteopathic Medicine in Erie, PA. My residency in Internal Medicine and fellowship in Hematology and Medical Oncology were both completed through the University at Buffalo. I hold board certifications in Internal Medicine, Hematology and Medical Oncology.

My research interests include Early Phase Clinical Trials for high-risk myeloid malignancies, as well as translational medicine. My translational work is focused on understanding how leukemic blasts modulate the local immune system to evade detection, and therefore identifying new therapeutic targets.


Roswell Park Comprehensive Cancer Center
  • Assistant Professor
  • Department of Medicine

Jacobs School Of Medicine And Biomedical Sciences, State University of New York at Buffalo

  • Assistant Professor
  • Department of Medicine


Education and Training:

  • 2011 - DO - Lake Erie College of Osteopathic Medicine, Erie, PA


  • 2014 - Internal Medicine - University at Buffalo, Buffalo, NY


  • 2017 - Hematology and Oncology - University at Buffalo, Buffalo, NY

Board Certification:

  • 2018 - Hematology
  • 2017 - Medical Oncology
  • 2016 - Internal Medicine

Professional Memberships:

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Society for Immunotherapy of Cancer

Professional Experience:

  • NCCN Acute Myeloid Leukemia Panel Member
  • NCCN Acute Lymphoblastic Leukemia Panel Member

Honors & Awards:

  • 2017 University at Buffalo Scholarly Exchange Day Research Award
  • 2017 Thomas F. Frawley Residency Research Fellowship
  • 2016 American Society of Hematology Abstract Award ASH Meeting on Hematologic Malignancies
  • 2015-2016 University at Buffalo GME Quality Improvement Award

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

Przespolewski A, Goldberg AD, Talati C, Fazal S, Vachhani P, Sanikommu SR, Thota S, Waksal JA, Ball BJ, Famulare CA, Stahl M, Baron J, Griffiths EA, Thompson JE, Sweet KL, Wang ES. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Blood. 2023 Mar 23;141(12):1489-1493. doi: 10.1182/blood.2022016678. PMID: 36493344.

Wiatrowski K, Kim TH, Przespolewski A. Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia. Front Oncol. 2022 May 19;12:826768. doi: 10.3389/fonc.2022.826768. PMID: 35664748; PMCID: PMC9160191.

Singh A, Herr MM, Griffiths EA, Przespolewski A, Faber MG, Mrad C, Wang ES, Hahn T, Thota S. Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Sci Rep. 2021 Dec 2;11(1):23284. doi: 10.1038/s41598-021-02497-4. PMID: 34857802; PMCID: PMC8639740.

Przespolewski AC, Portwood S, Wang ES. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Leuk Lymphoma. 2021 Nov 25:1-10. doi: 10.1080/10428194.2021.1992614. Epub ahead of print. PMID: 34818963.

Przespolewski A, Muppidi MR, Freyer CW, Ji W, Cronin TL, Thota S, Griffiths EA, Thompson JE, Ontiveros EP, Baron J, Elshoury A, Wang ES. Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leuk Lymphoma. 2021 Feb 16:1-6. doi: 10.1080/10428194.2021.1992614. Epub 2021 Nov 25. PMID: 34818963.